News AbbVie cuts $1.9bn+ deal with IGI for trispecific antibody AbbVie has signed another deal in its effort to build an industry-leading position in multispecific antibodies for blood cancers.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
